Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE.
Level 5 - mechanism / opinion, no new human data
Narrative guideline comparison without primary patient data or systematic review methodology
PubMed 28065547 · doi:10.1016/j.japh.2016.11.005
What was done
The authors conducted a comparative review of updated diabetes clinical practice guidelines from the American Diabetes Association–European Association for the Study of Diabetes (ADA/EASD) and the American Association of Clinical Endocrinologists–American College of Endocrinology (AACE/ACE).
What was found
The ADA/EASD guideline recommends stepwise therapy starting with metformin and escalating every 3 months, with an A1C goal of <=7.0%. The AACE/ACE guideline supports a broader initial medication choice, suggests initial dual therapy for A1C 7.5%–9.0% and triple therapy for A1C >9.0%, and sets an A1C goal of <=6.5%. Both guidelines incorporate SGLT2 inhibitors and affirm the cardiovascular and pancreatic safety of incretins as well as the safety of pioglitazone regarding bladder cancer risk.
Why it matters
It clarifies differing clinical strategies between the two major diabetes management frameworks, noting the ADA/EASD approach is structured for primary care whereas AACE/ACE caters to specialist settings.
Limits
The abstract describes a narrative comparison of guideline documents with no primary patient data, quantitative meta-analysis, or independent assessment of clinical outcomes.
Cited by
- contradicts The American Association of Clinical Endocrinologists advises against relying heavily on hemoglobin A1C testing.